Genomic heart disease drug developer Verve Therapeutics secured funding in a round led by GV, which also led its series A last year.
GV, a corporate venturing subsidiary of internet and technology group Alphabet, has led a $63m series A2 round for Verve Therapeutics, a US-based developer of genomic heart disease drugs.
F-Prime Capital, a subsidiary of investment and financial services firm Fidelity, also took part in the round, as did Arch Venture Partners, Biomatics Capital, Wellington Management and Casdin Capital.
Verve is combining genetics analysis and gene editing in order to develop therapeutics that will treat coronary heart disease by targeting genes…
